[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ageing-and-geriatric-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ageing-and-geriatric-health":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100625207","this-study-investigates--hydroxy--methylbutyrate-hmb-and-2-hydroxybenzylamine-2-hoba-when-administered-either-individually-or-in-combination-contributes-to-an-increased-quality-of-health-specifically-improving-muscular-strength-and-cognitive-functioning-in-adults-over-the-age-of-65-100625207",false,"NCT07419633","This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65.","The Effects of Beta-Hydroxy-Beta-methylbutyrate (HMB) and\u002For 2-hydroxybenzylamine (2-HOBA) on Markers of Health Span in Older Adults. A Randomized Control Trial.","H2AGE","Inclusion Criteria:\n\n•. 65 years of age\n\n* English or French speaking\n* Females not of childbearing potential\n* Willing to maintain current lifestyle and dietary habits, including level of physical activity, allowed medication\u002Fsupplements habits for the duration of the study\n\nExclusion Criteria:\n\n* Known cardiac diseases, known arterial fibrillation, hepatic diseases, immune diseases (e.g. Individuals with an acute infectious disease, autoimmune disease or are immune compromised), ulcers, asthma, gout, severe anemia, hay fever, nasal polyps.\n\n  * Chronic kidney disease \\[estimated glomerular filtration rate (GFR) \\\u003C 35 mL\u002Fmin\\].\n  * Neurological injury\u002Fdisorder with significant persistent neurological or functional deficit (e.g., stroke with hemiparesis, spinal cord injury, muscular dystrophy, myopathy, myasthenia gravis, Parkinson's disease, peripheral polyneuropathy).\n  * Neuropsychological condition and\u002For cognitive impairment that, in the QI's opinion, could interfere with study participation\n  * History of confirmed chronic obstructive pulmonary disease with a severity grade \\> 2 on the Medical Research Council Dyspnea Scale.\n  * Uncontrolled hypothyroidism or hyperthyroidism. Hypothyroid patients who have changed their dose of hormone replacement therapy in the 6 weeks before screening are not eligible.\n  * Underlying muscle diseases, including a history of or currently active myopathy (e.g., dermatomyositis, polymyositis, etc.) or muscular dystrophies.\n  * Confirmed rheumatoid arthritis, acquired immunodeficiency syndrome (AIDS), type 1 or type 2 diabetes mellitus.\n  * History of cancer in the last 6 months.\n  * Not on any medications including NHPs\u002Fliving with medical conditions that would compromise the study outcome or the safety of the research participant.\n  * Known allergy to study medication or its components (non-medicinal ingredients).\n  * Allergy to aspirin\u002Fsalicylate or if using other drugs containing acetylsalicylic acid or other salicylates and a history of ASA-sensitive asthma\u002Fbronchospasm\n\nThe following list of medications\u002FNHPs will be excluded (and weaned as seen necessary by the study physician) prior to and during the study:\n\n* Participants on newly initiated cholesterol-lowering medication will be excluded. Those on stable regimens for ≥3 months will be included and will be monitored for potential interactions as per the HMB monograph.\n* Medications associated with muscle weakness or immune effects (i.e., oral glucocorticoids).\n* Medications or supplements affecting skeletal muscle metabolism or weight including: Use of MAO-I's (monoamine oxidase inhibitors), additional consumption of 2-HOBA, Vitamin D or HMB, anabolic steroids, selective androgen receptor modulators (SARMs), corticosteroids, GLP-1s, or other weight loss medications).\n* Excessive protein supplementation (i.e., \\>2.0 g\u002Fkg\u002Fday).\n* All participants must be on a stable dose of allowed supplements\u002Fmedications for at least 3 months prior to enrollment. All concomitant therapies will be documented.\n\nNon-pharmacological interventions that could influence study outcomes (e.g., pulmonary rehabilitation, structured exercise programs) will not be permitted.\n\nParticipants undergoing such therapies will be excluded. Any new interventions started during the study must be reported and if judged inappropriate, will result in withdrawal from the trial.",true,"ALL","65 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","In this study, participants will be assigned to receive HMB, 2-HOBA, a combination of both, or a comparison supplement for a set period of time. During the study, participants will attend scheduled visits where researchers will assess muscle strength, physical function, and overall health. Blood samples may be collected to measure markers related to metabolism, inflammation, and oxidative stress. Study staff will also monitor safety and any side effects throughout the study.",[28,29,30,31,32],"Muscle","Cognitive Functioning","Geriatric","Ageing and Geriatric Health","Ageing",[34,28,35,36,37,38,39,40,41],"Health","Cognitive","Memory","natural product","ageing","natural","supplement","preservation","RECRUITING","2026-05-11",{"date":45,"type":46},"2026-05-14","ACTUAL",{"date":48,"type":46},"2026-03-06",{"date":50,"type":22},"2027-02-05",{"name":52,"class":53},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100631919","study-of-functional-decline-and-care-pathways-in-neurosurgical-patients-over-65-years-of-age-100631919","NCT07506941","Study of Functional Decline and Care Pathways in Neurosurgical Patients Over 65 Years of Age","A Prospective, Multicenter, and Transnational Study of Functional Decline and Care Pathways in Neurosurgical Patients Over 65 Years of Age","GENEUS 1","Inclusion criteria:\n\nAge ≥ 65 years at the time of admission Admission to a neurosurgery department in one of the participating centres (France, Spain, or Portugal), Affiliation with a national health-insurance or equivalent system Feasibility of follow-up at 3 months, Consent\u002Fnon-opposition for the study\n\nExclusion Criteria:\n\nTerminal illness (neurosurgical or not) with an estimated life expectancy of \\\u003C 3 months.\n\nLoss of autonomy prior to admission, established as ADL \\\u003C 3. For a patient admitted to the emergency hospital, ask him (or his caregiver) about his functional abilities before his condition deteriorated.\n\nLegal protection status (guardianship, trusteeship, or judicial protection) when such status prevents lawful consent or non-opposition.\n\nParticipation in another interventional clinical study whose procedures or follow-up could interfere with GENEUS 1 objectives or endpoints.\n\nSevere cognitive or communication impairment",{"count":64,"type":22},209,"OBSERVATIONAL","The GENEUS 1 study addresses this gap by characterizing the real-world profiles, outcomes, and care pathways of adults aged 65 years and older hospitalized in neurosurgery across France, Spain, and Portugal. This project represents the first multicentre, transnational initiative to integrate geriatric principles into neurosurgical practice and to evaluate both clinical and economic outcomes in this population.",[31],[69,70],"neurosurgery","geriatric medicine","NOT_YET_RECRUITING","2026-03-26",{"date":74,"type":46},"2026-04-02",{"date":76,"type":22},"2026-04-01",{"date":78,"type":22},"2027-12",{"name":80,"class":53},"University Hospital, Toulouse",6,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":18,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":54},"100602548","chinese-migrant-population-health-cohort-100602548","NCT07124949","Chinese Migrant Population Health Cohort","Inclusion Criteria:\n\n1. Permanent residents of Harbin or Hainan who will continue to reside in Harbin or Hainan for the next 5 years.\n2. Baseline age ≥60 years, with basic communication and comprehension abilities.\n3. No confirmed diagnosis of end-stage major organic diseases (e.g., advanced heart failure, advanced liver failure, advanced kidney failure, malignant tumors).\n4. Able to perform activities of daily living independently and capable of completing questionnaires and physical examinations.\n5. Willing to participate in the study, provide written informed consent, accept long-term follow-up, and provide biological specimens.\n\nExclusion Criteria:\n\n1. Occurrence of life-threatening acute events (e.g., myocardial infarction, acute heart failure, stroke) within the past 30 days.\n2. Currently receiving chronic treatment with antiviral drugs (e.g., for HIV) or antipsychotic medications.\n3. Presence of moderate to severe cognitive impairment preventing survey completion or follow-up cooperation.\n4. Current acute infectious diseases such as influenza or fever.\n5. Simultaneous participation in other interventional clinical studies.\n6. Refusal to sign informed consent or unwillingness to provide biological specimens.\n7. Any other condition deemed unsuitable for study participation by the investigators based on overall assessment.","60 Years","120 Years",{"count":91,"type":22},26000,"The Chinese Migrant Population Health Cohort is a prospective, multi-center study jointly initiated by Professor Yong Ji, President of Harbin Medical University, and Academician Guoqiang Chen, President of Hainan Medical University, in collaboration with regional partners. It targets older adults (≥60 years) who engage in seasonal migration between cold (Heilongjiang) and tropical (Hainan) regions. The primary objective is to investigate cardiovascular and metabolic disease risks, underlying biological and environmental mechanisms, and effective preventive strategies in this unique population.\n\nParticipants are recruited from both origin and destination sites and undergo standardized baseline assessments, including questionnaires, physical examinations, medical imaging, biospecimen collection (blood, stool, hair, nails), and environmental exposure monitoring. Longitudinal follow-up includes periodic reassessments, remote monitoring, and data linkage with hospital information systems to capture health outcomes.\n\nThe study aims to:\n\nDefine migration-related health risk profiles and disease phenotypes.\n\nElucidate biological and environmental mechanisms influencing disease onset and progression.\n\nDevelop AI-driven risk prediction models and evaluate targeted interventions through nested randomized controlled trials.\n\nTranslate findings into clinical guidelines and scalable cross-regional health management models.\n\nThis is the first cohort in China to systematically investigate the health impacts of seasonal migration in older adults. By integrating epidemiology, multi-omics, environmental data, and health policy translation, the study seeks to improve continuity of care, strengthen climate adaptation, and promote healthy ageing.",[94,95,31,96],"Cardiovascular Diseases","Metabolic Disorders","Climate Adaptation",[94,98,99,100,101,102],"Metabolic Diseases","Geriatrics","Migration","Climate Change","Health Promotion","2025-08-14",{"date":105,"type":46},"2025-08-20",{"date":107,"type":46},"2025-07-23",{"date":109,"type":22},"2030-04-30",{"name":111,"class":53},"Jinwei Tian"]